Diamedica Therapeutics Inc (DMAC)

$7.09 -0.19 (-2.61%)
Market Cap 366.48M
Revenue (ttm) 0.00
Net Income (ttm) -24.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 418,900
Avg Vol 413,618
Day's Range N/A - N/A
Shares Out 51.69M
Stochastic %K 83%
Beta 1.40
Analysts Strong Sell
Price Target $12.33

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human...

Industry: Biotechnology
Sector: Healthcare
Phone: 763 496 5454
Address:
301 Carlson Parkway, Suite 210, Minneapolis, United States
TwoToesTrading
TwoToesTrading Sep. 12 at 11:19 AM
$DMAC $SPY DMAC 20% move off the break this week See it now?
1 · Reply
Relee187200
Relee187200 Sep. 11 at 6:47 PM
$DMAC Maybe Cooperman is selling!!!
1 · Reply
StockArbitrage
StockArbitrage Sep. 9 at 3:01 AM
$DMAC
0 · Reply
Viter
Viter Sep. 8 at 7:48 PM
$DMAC Here:
0 · Reply
Sicksir
Sicksir Sep. 8 at 6:22 PM
$DMAC Leon Cooperman on CNBC overall bearish on the broader market, but highlighting DMAC as one of his very few value plays tells you everything you need to know. https://www.msn.com/en-us/money/news/billionaire-investor-leon-cooperman-the-broader-market-is-heading-for-trouble/vi-AA1M7dx5?ocid=socialshare
0 · Reply
Sasquamch
Sasquamch Sep. 8 at 5:26 PM
$DMAC Who was this coolagen guy pumping this?
0 · Reply
StockArbitrage
StockArbitrage Sep. 8 at 4:30 PM
$GNPX Don't fret. Traders will be bored with their eye scanning crypto AI orbs company soon enough. A lot of potential here. Nice fast track IMO. I like this and $DMAC for unmet needs for strokes. https://www.genprex.com/wp-content/uploads/2025/07/2025-Shareholder-Letter_FINAL.pdf
0 · Reply
topstockalerts
topstockalerts Sep. 8 at 1:31 PM
$DMAC this setup continues to provide opportunities.. stay tuned!
0 · Reply
GSP
GSP Sep. 8 at 1:28 PM
$HOUR $HOOD $XAIR $DMAC
0 · Reply
GSP
GSP Sep. 8 at 1:09 PM
Latest gapper list for today (con't): $HOUR $HOOD $XAIR $DMAC .
0 · Reply
Latest News on DMAC
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

Sep 5, 2025, 8:30 AM EDT - 8 days ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

Sep 2, 2025, 8:23 AM EDT - 11 days ago

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

Aug 13, 2025, 3:58 PM EDT - 4 weeks ago

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 11:36 AM EDT - 4 weeks ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:15 PM EDT - 4 weeks ago

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Aug 6, 2025, 8:00 AM EDT - 5 weeks ago

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

Aug 5, 2025, 4:15 PM EDT - 5 weeks ago

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

Jul 23, 2025, 4:30 PM EDT - 7 weeks ago

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

Jul 21, 2025, 8:00 AM EDT - 7 weeks ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jul 17, 2025, 8:00 AM EDT - 2 months ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Jun 24, 2025, 8:30 AM EDT - 2 months ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 22, 2025, 8:30 AM EDT - 4 months ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 19, 2025, 9:00 AM EDT - 4 months ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 4:30 PM EDT - 4 months ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

May 14, 2025, 11:05 AM EDT - 4 months ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 13, 2025, 4:30 PM EDT - 4 months ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 8, 2025, 4:00 PM EDT - 4 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

May 7, 2025, 8:30 AM EDT - 4 months ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 10:27 AM EDT - 6 months ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 17, 2025, 4:30 PM EDT - 6 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Mar 11, 2025, 8:23 AM EDT - 6 months ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 24, 2025, 8:30 AM EST - 7 months ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 20, 2025, 8:15 AM EST - 7 months ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:15 PM EST - 7 months ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Dec 3, 2024, 8:25 AM EST - 10 months ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 12:49 PM EST - 10 months ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:20 PM EST - 10 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 13, 2024, 4:05 PM EST - 10 months ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 12, 2024, 8:23 AM EST - 10 months ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Nov 6, 2024, 8:32 AM EST - 11 months ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Oct 9, 2024, 8:27 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics Upcoming Conference Participation

Sep 4, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Upcoming Conference Participation

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 7, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Aug 1, 2024, 8:20 AM EDT - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

Jul 11, 2024, 2:48 PM EDT - 1 year ago

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 11, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jul 1, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:15 AM EDT - 1 year ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

Jun 26, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

May 11, 2024, 4:49 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 8, 2024, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

May 2, 2024, 8:55 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Apr 17, 2024, 4:08 PM EDT - 1 year ago

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:14 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Mar 19, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Jan 29, 2024, 4:13 PM EST - 1 year ago

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Jan 22, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 12:10 PM EST - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Nov 13, 2023, 4:28 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Nov 9, 2023, 8:25 AM EST - 2 years ago

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

TwoToesTrading
TwoToesTrading Sep. 12 at 11:19 AM
$DMAC $SPY DMAC 20% move off the break this week See it now?
1 · Reply
Relee187200
Relee187200 Sep. 11 at 6:47 PM
$DMAC Maybe Cooperman is selling!!!
1 · Reply
StockArbitrage
StockArbitrage Sep. 9 at 3:01 AM
$DMAC
0 · Reply
Viter
Viter Sep. 8 at 7:48 PM
$DMAC Here:
0 · Reply
Sicksir
Sicksir Sep. 8 at 6:22 PM
$DMAC Leon Cooperman on CNBC overall bearish on the broader market, but highlighting DMAC as one of his very few value plays tells you everything you need to know. https://www.msn.com/en-us/money/news/billionaire-investor-leon-cooperman-the-broader-market-is-heading-for-trouble/vi-AA1M7dx5?ocid=socialshare
0 · Reply
Sasquamch
Sasquamch Sep. 8 at 5:26 PM
$DMAC Who was this coolagen guy pumping this?
0 · Reply
StockArbitrage
StockArbitrage Sep. 8 at 4:30 PM
$GNPX Don't fret. Traders will be bored with their eye scanning crypto AI orbs company soon enough. A lot of potential here. Nice fast track IMO. I like this and $DMAC for unmet needs for strokes. https://www.genprex.com/wp-content/uploads/2025/07/2025-Shareholder-Letter_FINAL.pdf
0 · Reply
topstockalerts
topstockalerts Sep. 8 at 1:31 PM
$DMAC this setup continues to provide opportunities.. stay tuned!
0 · Reply
GSP
GSP Sep. 8 at 1:28 PM
$HOUR $HOOD $XAIR $DMAC
0 · Reply
GSP
GSP Sep. 8 at 1:09 PM
Latest gapper list for today (con't): $HOUR $HOOD $XAIR $DMAC .
0 · Reply
loweone
loweone Sep. 8 at 1:08 PM
$DMAC Did i hear him correctly, he said he was shorting DMAC, Lee cooperman?
1 · Reply
DisMania
DisMania Sep. 8 at 12:47 PM
$DMAC If it's good enough for Lee Cooperman....
0 · Reply
RJRNAB
RJRNAB Sep. 8 at 12:44 PM
$DMAC A little Cooperman DMAC plug on CNBC doesn't hurt
0 · Reply
nailman
nailman Sep. 8 at 4:46 AM
$DMAC they lie if you wanna reduce your blood pressure use cayenne pepper all of the shit that they’re trying to do is garbage. It’s not about stocks anymore guys it’s about actual helping people and they’re lying.
1 · Reply
TwoToesTrading
TwoToesTrading Sep. 6 at 1:50 PM
$DMAC $SPY I prob won’t play this name- but hard to ignore the setup- it’s absolutely there if the company doesn’t mess this up-
0 · Reply
Sukitt
Sukitt Sep. 5 at 11:56 PM
$DMAC Well, another good day folks. Let your own DD be your guide.
0 · Reply
Sukitt
Sukitt Sep. 5 at 6:45 PM
$DMAC
0 · Reply
MEC1069
MEC1069 Sep. 5 at 3:59 PM
$DMAC There she go's ✈️ with +20 million of inside buys last 2 months this will be a runner!
0 · Reply
StockArbitrage
StockArbitrage Sep. 5 at 3:45 PM
$DMAC
0 · Reply
AZOZ
AZOZ Sep. 5 at 11:32 AM
$DMAC insider activity!
0 · Reply
MedCred
MedCred Sep. 4 at 10:19 PM
$DMAC Gear fire side chat describing the preeclampsia and stroke programs and potential https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=15986889&checkCompany=1&checkEmail=1&checkName=1
0 · Reply
Sukitt
Sukitt Sep. 4 at 8:02 PM
$DMAC The Cantor Global Healthcare Conference presentation was very informing. With investor patience, rinvecalinase, as a treatment for preeclampsia and stroke, should become a game changer, if not standard of care, for patients. Long hold. 💪🏻💎DYOD.
1 · Reply